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globulin light chains predicted mortality in hemodialysis pa-
tients.  Conclusion: Higher serum levels of free   plus   im-
munoglobulin light chains ameliorate survival in hemodialy-
sis patients.  Copyright © 2011 S. Karger AG, Basel 
 Plasma cells develop from stem cells in bone marrow. 
Plasma cells produce immunoglobulins, which consist of 
two identical heavy chains and light chains. There are 
two types of light chains:   and   light chains. In addition 
to the light chains as part of the immunoglobulins, low 
levels of free immunoglobulin light chains are produced 
in slight excess of heavy chains and thus circulate in the 
blood. Measurements of free immunoglobulin light 
chains have improved diagnosis and monitoring of the 
course of many monoclonal gammopathies. Measure-
ments of the serum levels of free immunoglobulin light 
chains are now part of recommendations concerning the 
diagnosis of monoclonal gammopathies  [1, 2] .
 Free   light chains are monomeric, while free   light 
chains are mainly dimeric. As a consequence of the lower 
molecular weight of the   -monomers the glomerular fil-
tration rate for   is three times as high as for   light chain 
dimers. Light chains are filtered by the kidney glomeruli 
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 Abstract 
 Background/Aims: Impaired immune function is common 
in patients with chronic renal failure. Now, we determined 
whether serum levels of free immunoglobulin light chains 
predict mortality in patients with chronic kidney disease 
stage 5 on hemodialysis.  Methods: We performed a pro-
spective cohort study of 160 hemodialysis patients with a 
median follow-up of 15 months (interquartile range, 3–44 
months). Serum levels of free   and   immunoglobulin light 
chains were measured at the start of the study. The primary 
end point was mortality from any cause.  Results: In survi-
vors, median serum levels of free   plus   immunoglobulin 
light chains were significantly higher compared with non-
survivors (p  ! 0.05). Survival was significantly longer in those 
patients who had serum levels of free   plus   immunoglob-
ulin light chains above the median compared with patients 
with serum levels below the median of 210 mg/l (  2 = 5.91;
p = 0.015 by log-rank, Mantel-Cox, test). We performed uni-
variate and multivariate regression analysis showing that 
older age and lower serum levels of free   plus   immuno-
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and afterwards reabsorbed by the proximal tubuli medi-
ated by megalin-cubulin receptor endocytosis and me-
tabolized  [3] . Only if the serum concentration of free light 
chains is greatly increased, the absorption maximum of 
the kidney is exceeded and free light chains are excreted 
by the urine. Due to reduced free light chain clearances, 
patients with chronic kidney disease have increased levels 
of serum free immunoglobulin light chains. Previous 
studies showed that the increased serum concentrations 
of free immunoglobulin light chains correlate with pa-
rameters of kidney function including creatinine and 
cystatin C  [3, 4] . Several factors have been established that 
predict mortality in hemodialysis patients  [5, 6] . How-
ever, currently the consequences of increased serum con-
centrations of free immunoglobulin light chains for life 
expectancy in patients with chronic kidney disease re-
main unknown. Therefore, we prospectively evaluated 
the role of the serum concentrations of free   and   im-
munoglobulin light chains as an independent predictor 
of mortality in 160 patients with chronic kidney disease 
stage 5 on hemodialysis.
 Subjects and Methods 
 Patients 
 We prospectively studied 160 patients with chronic kidney 
disease stage 5 on hemodialysis treatment. All subjects gave writ-
ten informed consent, and the study was approved by the local 
ethics committee. 112 were male and 48 were female, median age 
was 67 years (interquartile range 56–76 years). Dialyses were per-
formed using standardized techniques with bicarbonate-based 
dialysates and controlled ultrafiltration rate. Blood flow rates 
were 250–300 ml/min, dialysate flow rates were 500 ml/min, and 
dialysate conductivity was 135 mS/cm. Patient dry weight was de-
fined as the body weight below which the patient experienced hy-
potension or muscle cramps, and postural hypotension was clin-
ically manifest. Patient history was assessed by trained personnel 
using medical records and a standardized questionnaire, and 
comprised personal history and previous history of cardiovascu-
lar disease, including coronary artery disease, angina pectoris 
and peripheral vascular and cerebrovascular disease. Blood pres-
sure was measured before dialysis with a sphygmomanometer af-
ter 10 min of recumbency. Phases I and V of the Korotkoff sounds 
were taken as systolic and diastolic blood pressure, respectively. 
Pulse pressure was calculated as the difference between systolic 
and diastolic blood pressure. Blood samples were taken before the 
hemodialysis session. Kt/V values, i.e. the amount of plasma 
cleared of urea divided by the urea distribution volume, was mea-
sured according to the formula Kt/V = –ln (R – 0.03) + (4 – 3.5  ! 
R)  ! UF/W, where R = post-/pre-plasma urea nitrogen ratio,
UF = ultrafiltrate volume (liters) removed, and W = postdialysis 
weight (kg)  [7] . To be included in the study, patients needed to 
have chronic kidney disease stage 5 and to be routinely dialyzed 
for 4–5 h three times weekly using biocompatible polysulfone low 
flux membrane (F8, Fresenius Medical Care; ultrafiltration coef-
ficient, 7 ml/h/mm Hg; surface area, 1.0 m 2 ) with no dialyzer re-
use. Patients were ambulatory and free of acute intercurrent ill-
ness. Both male and female patients were included. Patients who 
did not give written consent were excluded from the study. Pa-
tients with known or already treated monoclonal gammopathies 
were excluded.
 Measurement of Serum Free Immunoglobulin Light Chains 
 Serum levels of free   and   immunoglobulin light chains were 
measured by nephelometry as described  [8] . We used a particle-
enhanced, high-specificity, homogenous immunoassay accord-
ing to the recommendations of the manufacturer. The assay sen-
sitivity was less than 1 mg/l  [9] . The manufacturer of the immu-
noassay (Freelite; The Binding Site, Birmingham, UK) provided 
the assay for determination of serum levels of free   and   immu-
noglobulin light chains. The company had no role in the design 
of the study or the collection, analysis, or interpretation of the 
data or the writing of the manuscript. The authors vouch for the 
accuracy and completeness of the reported data. 
 Statistics 
 Data were expressed as the median and interquartile range. 
Statistical analyses were performed using GraphPad Prism 5.0 
(GraphPad Software, San Diego, Calif., USA) or SPSS for Win-
dows (version 15.0; SPSS, Chicago, Ill., USA). Data on free immu-
noglobulin light chains were analyzed using the D’Agostino-
Pearson normality test. Because data on free light chains did not 
show Gaussian distribution (K2 = 234, p  ! 0.0001), data were 
transformed logarithmically. Between groups, comparisons were 
made using the nonparametric Mann-Whitney test. The relation-
ships between serum concentrations of free   plus   immuno-
globulin light chains and other variables were analyzed by non-
parametric Spearman correlation. Categorical variables compris-
ing gender (male = 1, female = 2) and diabetes (yes = 1, no = 0) 
were compared using Fisher’s exact test. A p value less than 0.05 
was taken to indicate statistical significance. All statistical tests 
were two sided.
 The outcome event investigated was all-cause mortality. This 
outcome event was specified a priori. Survival curves (time-to-
event analysis) were generated using the Kaplan-Meier product 
limit method and compared by the log-rank (Mantel-Cox) test. 
For the Kaplan-Meier analysis, the cohort was divided into two 
groups according to serum levels of free   plus   immunoglobulin 
concentrations above or below the median value.
 The analysis used the unadjusted Cox proportional hazards 
analysis. Multivariate Cox proportional hazard analysis was then 
applied to determine the independence of the relationship of all 
covariates. Covariates were selected on the basis of prior research 
results, clinical experience and classical clinical performance mea-
sures, and included age, Kt/V urea value, gender, smoking, diabe-
tes mellitus, previous cardiovascular disease and pulse pressure. 
In a stepwise forward regression analysis, variables with a p value 
less than 0.05 were retained. Adjusted relative risks were calcu-
lated as the antilogarithm of the   -coefficient of the Cox-propor-
tional hazards regression analysis. The 95% confidence interval for 
the relative risk estimates was obtained using the antilogarithm (  
 8 1.96  ! standard error of   ). Each significant predictor identi-
fied by that analysis was subsequently tested in a backward selec-
tion process with all covariates forced into the model.
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 Results 
 We investigated the outcome of patients with chronic 
kidney disease stage 5 on hemodialysis treatment accord-
ing to the serum concentrations of free   and   immuno-
globulin light chains in a prospective cohort study. A to-
tal of 160 patients with chronic kidney disease stage 5 (112 
males, 48 females; median age, 67 years; interquartile 
range, 56–76 years) who were receiving hemodialysis for 
at least 1 month were enrolled in the study. The cause of 
end-stage renal disease was diabetic nephropathy in 29 
cases (18%), nephrosclerosis in 62 cases (39%), chronic 
glomerulonephritis in 17 cases (11%), polycystic kidney 
disease in 4 cases (3%), and other/unknown in 48 cases 
(30%). Angiotensin-converting enzyme inhibitors were 
prescribed in 47 cases (29%), beta-blockers in 83 cases 
(52%), calcium channel blockers in 48 cases (30%) and 
erythropoietin therapy in 95 cases (59%). The median du-
ration of hemodialysis at inclusion was 7 months (inter-
quartile range, 1–38 months). 144 previous cardiovascu-
lar events were reported in 160 patients (90%), including 
a history of coronary artery disease (72 cases, 45%), pe-
ripheral vascular disease (35 cases, 22%) and cerebrovas-
cular disease (27 cases, 17%). Patients with known or al-
ready treated monoclonal gammopathies were excluded 
from the study. The clinical and biochemical character-
istics of the patients are summarized in  table 1 . Median 
Kt/V was 1.1 (interquartile range, 1.0–1.2).
 In 160 patients, the median serum level of free   light 
chains was 107 mg/l (interquartile range, 64–182 mg/l), 
and for free   light chains it was 72 mg/l (interquartile 
range, 42–139 mg/l). The median serum level of free   
plus   immunoglobulin light chains was 210 mg/l (inter-
quartile range, 116–316 mg/l). Next, we assessed factors 
that may influence serum levels of free immunoglobulin 
light chain in hemodialysis patients. We found that se-
rum levels of free   plus   immunoglobulin light chains 
were significantly correlated with age (Spearman r = 
–0.17; 95% CI –0.32 to –0.01; p  ! 0.05) but not with Kt/V 
(Spearman r = 0.07; 95% CI –0.10 to 0.23; p = 0.42) or 
pulse pressure (Spearman r = 0.10; 95% CI –0.07 to 0.27; 
p = 0.22). 
 Now, we evaluated whether the serum levels of free   
and   immunoglobulin light chains predicted mortality 
in hemodialysis patients. Data on mortality were ob-
tained for the entire cohort. During follow-up (median, 
15 months; interquartile range, 3–44 months), 87 patients 
(54%) died. The cause of death was cardiovascular disease 
in 44 patients (51%), infections in 31 patients (36%), can-
cer in 9 patients (10%), and other or unknown in 3 pa-
tients (3%). Nine patients (6%) underwent kidney trans-
plantation during follow-up. Those patients were cen-
sored on the day of transplantation. In survivors, serum 
levels of free   plus   immunoglobulin light chains were 
significantly higher (median, 230 mg/l; interquartile 
range, 141–369 mg/l; n = 73) compared with nonsurvi-
vors (median, 183 mg/l; interquartile range, 86–293 mg/l; 
n = 87; p  ! 0.05). These data indicated that lower serum 
levels of   plus   free immunoglobulin light chains were 
associated with increased mortality.
 Figure 1 a shows the probabilities of survival of patients 
with chronic kidney disease stage 5 on hemodialysis ac-
cording to the serum level of free   plus   immunoglobu-
lin light chains. Survival was significantly longer in pa-
tients with serum levels of free   plus   immunoglobulin 
light chains above the median value (i.e. above 210 mg/l) 
compared to patients with serum levels below the median 
(  2 = 5.91; p = 0.015 by log-rank, Mantel-Cox, test). Me-
dian survival in the group with serum levels of free   plus 
  immunoglobulin light chains above 210 mg/l was 43 
months, whereas median survival in the group with se-
rum levels below 210 mg/l was 27 months. As indicated 
in  figure 1 b, c, patients with   immunoglobulin light 
chains above median or   immunoglobulin light chains 
above median showed marginally significant improved 
survival, p = 0.066 or p = 0.054 by log-rank (Mantel-Cox) 
test, respectively.
Table 1.  Clinical and biochemical characteristics of 160 patients 
with chronic kidney disease stage 5 on hemodialysis
Characteristic Median (interquartile range)
Age, years 67 (56–76)
Male/female 112/48
BMI 24.1 (20.9–26.5)
Duration of hemodialysis, months 7 (1–38)
Systolic blood pressure, mm Hg 130 (113–150)
Diastolic blood pressure, mm Hg 69 (57–80)
Pulse pressure, mm Hg 61 (50–71)
Hemoglobin, g/dl 10.1 (9.2–11.6)
Serum albumin, g/dl 3.3 (2.9–3.8)
Serum cholesterol, mg/dl 154 (129–186)
Serum triglyceride, mg/dl 159 (106–230)
, mg/l 107 (64–182)
, mg/l 72 (42–139)
 plus , mg/l 210 (116–316)
 = Free  immunoglobulin light chains;  = free  immuno-
globulin light chains.
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 The unadjusted Cox proportional hazards analysis 
identified age and the logarithmically transformed se-
rum levels of free   plus   immunoglobulin light chains 
as significantly associated with mortality ( table 2 ). Next, 
we used adjusted Cox proportional hazards analysis of 
all-cause mortality. The multivariate analysis showed 
that age (p  ! 0.001) and the logarithmically transformed 
serum levels of free   plus   immunoglobulin light chains 
(p = 0.036) significantly predicted mortality in patients 
with chronic kidney disease stage 5 on hemodialysis ( ta-
ble  3 ). Multivariate analysis confirmed that both older 
age and lower logarithmically transformed serum levels 
of free   plus   immunoglobulin light chains were associ-
ated with increased mortality.
 Discussion 
 The purpose of this prospective cohort study of 160 
patients was to assess whether serum levels of free immu-
noglobulin light chains predict mortality in patients with 
chronic kidney disease stage 5 on hemodialysis. This 
study is the first to show that serum levels of free   plus 
  immunoglobulin light chains significantly predicted 
mortality in these patients. Univariate as well as multi-
variate regression analysis showed that older age and low-
er serum levels of free   plus   immunoglobulin light 
chains predict mortality in hemodialysis patients. It 
should be noted that patients with known or already 
treated monoclonal gammopathies were excluded from 
the present study.
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 Fig. 1. Kaplan-Meier survival curve for all-cause mortality in pa-
tients with chronic kidney disease stage 5 on hemodialysis ac-
cording to free   and   immunoglobulin light chain serum levels. 
 a Patients with serum values of free   plus   immunoglobulin 
light chains above median show significantly improved survival. 
p = 0.015 by log-rank (Mantel-Cox) test. Patients with   immuno-
globulin light chains above median ( b ) or   immunoglobulin 
light chains above median ( c ) showed marginally significant im-
proved survival. p = 0.066 or p = 0.054 by log-rank (Mantel-Cox) 
test, respectively. 
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 An immunoassay which detects free light chains has 
been available since 2001  [8] . Hutchison et al. [3] assessed 
free light chains in patients with chronic kidney disease 
of diverse etiology. They showed a positive correlation be-
tween serum levels of free   and   immunoglobulin light 
chains and renal impairment parameters including cre-
atinine and cystatin C. In patients with chronic kidney 
failure, a gradual increase in the median serum free light 
chain levels was observed. It was noticed that patients 
who were already on a dialysis schedule showed signifi-
cantly higher free light chain concentrations than pa-
tients classified as CKD stage 5 but not yet on hemodi-
alysis treatment.
 Why do hemodialysis patients with higher serum lev-
els of free   plus   immunoglobulin light chains show 
improved survival? A recent study by Lorenzen et al.  [10] 
indicated that several traditional risk factors did not af-
fect incident cardiovascular events including death in he-
modialysis patients. Therefore, other factors, including 
free light chains, may be more important for the survival 
of hemodialysis patients. Several mechanisms may con-
tribute to this finding. First, reduced serum levels of free 
  and   immunoglobulin light chains may indicate glob-
al impairment of bone marrow function probably due
to long-standing uremia. Several groups established im-
paired immunoglobulin production by B cells from he-
modialysis patients  [11, 12] . Impaired immunoglobulin 
production by B cells has been associated with secondary 
hyperparathyroidism in hemodialysis patients  [11, 12] . 
Therefore, it is likely that higher levels of free   and   im-
munoglobulin light chains may reflect lower uremic tox-
icity and thus improved survival. In turn, long-standing 
increased uremia may be monitored by reduced immu-
noglobulin light chain levels leading to increased mortal-
ity. Second, Cohen et al. [13] showed that   and   immu-
noglobulin light chains increased the percentage of viable 
polymorphonuclear leukocytes by inhibiting apoptosis 
in a concentration-dependent manner. The increased 
number of viable polymorphonuclear leukocytes may be 
beneficial for combating bacterial infections. It is well 
known that infections are a leading cause of mortality
in hemodialysis patients. Third, immunoglobulin light 
chains have been reported to activate mast cells  [14] . Re-
cent studies revealed the potential of mast cells to pro-
duce prompt inflammatory responses and to fight in-
fections in the early stages of sepsis  [15] . Therefore, en-
forcing mast cell activation by higher   and   immu-
noglobulin light chain levels may facilitate relief from 
bacterial infections. Further experimental and clinical 
studies are needed to clarify the role of free light chains 
in the outcome of hemodialysis patients. 
 In conclusion, higher serum levels of free   plus   im-
munoglobulin light chains improve survival in hemodi-
alysis patients.
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Table 2. U nivariate Cox proportional hazards analysis of all-
cause mortality in patients with chronic kidney disease stage 5 on 
hemodialysis treatment
Variable Wald
Z value
p RR (95% CI)
Age 26.82 0.000 1.065 (1.040–1.091)
Log ( plus ) 4.383 0.036 0.447 (0.210–0.950)
Gender
(1 = male; 2 = female) 1.728 0.189 0.687 (0.392–1.203)
Kt/V 0.022 0.882 0.916 (0.289–2.909)
Smoking (1 = yes; 0 = no) 0.677 0.411 0.781 (0.433–1.408)
Diabetes (1 = yes; 0 = no) 0.765 0.382 1.274 (0.740–2.194)
CVD (1 = yes; 0 = no) 0.728 0.393 0.798 (0.474–1.341)
Pulse pressure 1.796 0.180 0.991 (0.979–1.004)
L og ( plus ) indicates the logarithm of serum levels of free  
plus  immunoglobulin light chains. Kt/V = Dialysis dose. CVD 
indicates history of cardiovascular disease (events).
Table 3. A djusted Cox proportional hazards analysis of all-cause 
mortality in patients with chronic kidney disease stage 5 on he-
modialysis
Variable Wald Z value p RR (95% CI)
Age 28.241 <0.001 1.059 (1.037–1.081)
Log ( plus )  4.548 0.033 0.451 (0.217–0.938)
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